This article was originally published in Pharmaceutical Approvals Monthly
Anastrozole is approved Sept. 1 for first-line treatment of locally advanced or metastatic breast cancer in postmenopausal women with hormone receptor positive or hormone receptor unknown disease. The company will submit annual safety and survival updates on its pivotal studies to FDA until 75% of study patients are deceased. The aromatase inhibitor was originally approved in 1996 for use following failure on AstraZeneca's Nolvadex (tamoxifen
You may also be interested in...
Most clinical trial sponsors view data disclosure as a mandate, maintaining regulatory compliance as a legal requirement. Study sponsors that realize the potential to repurpose this data, using a patient-first approach, turn transparency into a strategic advantage for engagement and recruitment efforts.
The Bio-Console 560 extracorporeal blood pumping console is being recalled over reports it could lose power during bypass surgery, which could lead to organ or neural dysfunction, blood clots, or even death.
House passes “SAFE Banking” Act sponsored by Rep. Ed Perlmutter to allow cannabis- and hemp-related businesses in states with some form of legalized marijuana to access financial services by creating protections for those institutions. Sen. Jeff Merkley introduced the same legislation in March.